ମୁଣ୍ଡ ଓ ବେକ କ୍ୟାନ୍ସର
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ ଭାରତରେ ୬ଟି hospital ରୋଗୀଙ୍କୁ ନେଉଛନ୍ତି.
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
ସ୍ପୋନ୍ସର: ଜାନସେନ୍ ରିସର୍ଚ୍ଚ ଆଣ୍ଡ ଡେଭେଲପମେଣ୍ଟ, LLC
ClinicalTrials.gov ରେ NCT07276399
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 25 Sep 2026 · ଆମେ ପଢିଲୁ 20 Oct 2026